Patents Assigned to Brainever
  • Publication number: 20260216281
    Abstract: The present invention relates to Engrailed protein, a nucleic acid encoding Engrailed protein and compositions comprising the same for use in treating or preventing diseases associated with accumulation of TDP-43 in the cell, particularly in the cell cytoplasm. Also provided herein are in vitro methods of selecting a subject for such therapy by detecting cellular accumulation of TDP-43, particularly cellular cytoplasmic accumulation, in a biological sample of the subject. Also provided herein are in vitro methods of following a subject treated with such therapy by measuring cellular accumulation, particularly cellular cytoplasmic accumulation, of TDP-43 in a biological sample of the treated subject.
    Type: Application
    Filed: January 22, 2026
    Publication date: July 30, 2026
    Applicants: Brainever, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, COLLEGE DE FRANCE
    Inventors: Stéphanie Vargas Abonce, Alain Prochiantz